outcomes from a Phase 2 thought ev...
outcomes from a Phase 2 thought evaluating Herceptin (trastuzumab, Genentech Inc., southern San Francisco, CA) in combination with Navelbine (vinorelbine) point out to that the combination therapy was well tolerated in the control population. The single-arm study evaluated the combination as preoperative, neoadjuvant therapy for early-stage HER2-positive breast cancer, followed by dint of mastectomy with postoperative
|